Citadel Advisors’s Lixte Biotechnology Warrants LIXTW Stock Holding History

Citadel Advisors’s Portfolio LIXTW Stock Details LIXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,231	Closed	-$722	–	13529
2025 Q2	$722	Sell	25,231 -801	-3%	-$26	﹤0.01%	12279
2025 Q1	$880	Sell	26,032 -1,300	-5%	-$44	﹤0.01%	14203
2024 Q4	$793	Sell	27,332 -809	-3%	-$26	﹤0.01%	14268
2024 Q3	$1.46K	Sell	28,141 -3,981	-12%	-$189	﹤0.01%	13849
2024 Q2	$1.99K	Buy	+32,122	New	+$2.1K	﹤0.01%	13751
2023 Q2	–	Sell	-11,067	Closed	-$664	–	14852
2023 Q1	$664	Buy	+11,067	New	+$1.26K	﹤0.01%	14441

Other funds holding LIXTW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's LIXTW Position: Q3 2025 in Review

Citadel Advisors sold out of Lixte Biotechnology Warrants (LIXTW) in Q3 2025, closing a stake of 25,231 shares — an estimated $722 sold.

Citadel Advisors first reported a position in LIXTW in Q1 2023 and held it in 6 quarters. The position peaked at $1.99K in Q2 2024. 3 funds tracked by Wall St. Rank hold LIXTW as of Q3 2025.

Citadel Advisors reported no remaining Lixte Biotechnology Warrants position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 25,231 Lixte Biotechnology Warrants shares in Q3 2025, an estimated $722.
Citadel Advisors first reported a position in Lixte Biotechnology Warrants in Q1 2023 and held it in 6 quarters.
Citadel Advisors's Lixte Biotechnology Warrants position peaked at $1.99K in Q2 2024.
3 funds tracked by Wall St. Rank held Lixte Biotechnology Warrants as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.